Novo Nordisk has announced the expansion of its insulin production facility in Kalundborg, Denmark, to meet rising global demand for diabetes treatments. The project, which involves an investment of over €2 billion, aims to increase manufacturing capacity for both current and future insulin products.

The expansion is expected to create approximately 400 new jobs and will incorporate advanced manufacturing technologies to enhance efficiency and sustainability. Novo Nordisk has emphasized its commitment to reducing environmental impact by integrating energy-efficient systems and sustainable building practices throughout the facility.

This development underscores the ongoing need for scalable diabetes care solutions and reflects the company's long-term strategy to support patients worldwide. For more information, visit Novo Nordisk Newsroom.